Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 19, 2005. The document serves as a report of foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The primary content consists of multiple "Schedule 5 Blocklisting Six Monthly Returns" submitted to the UK Listing Authority and Financial Services Authority, covering the period from July 1, 2004, to December 31, 2004. The filing details the status of various employee share option schemes and reports changes in directors' interests.
Key Financial Metrics
The filing text does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly administrative regarding equity compensation plans. However, it does report the following equity-related figures:
- Total Shares in Issue: Approximately 5,937,688,831 ordinary shares (confirmed across multiple schedules).
- Shares Issued Under Schemes (July 1 – Dec 31, 2004):
- Glaxo Wellcome International Share Option Scheme: 831,083
- Glaxo Group Limited Share Option Scheme: 918,347
- SmithKline Beecham 1989 Executive Share Option Plan (Approved): 469,577
- SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - ADS): 922,341
- SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - Ordinary): 315,267
- GlaxoSmithKline Share Option Plan - ADS: 296,276
- Glaxo Wellcome UK Share Option Scheme: 20,035
- GlaxoSmithKline Savings Related Share Option Scheme: 79,779
- Directors' Interests: On January 18, 2005, the GSK Trust transferred 19,638 ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Material Changes
The filing does not contain comparative financial data to assess material changes in revenue or profitability. The only reported changes relate to the administration of share option schemes:
- Several schemes reported zero shares issued during the period (e.g., GlaxoSmithKline Share Option Plan - Ordinary Shares, Glaxo Wellcome UK Savings Related Share Option Plan).
- One scheme, the SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - ADS), reported a negative balance of (195,347) shares not yet issued at the end of the period, indicating issuances exceeded the blocklisted amount available at the start of the period.
- Multiple blocklisting dates are referenced, including new blocklistings on November 4, 2004, for several plans.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is limited to statutory reporting of share scheme mechanics and director share movements.
Important Facts for Investor Verification
- Verify the total number of shares outstanding (5,937,688,831) against the company's most recent annual report (Form 20-F) to ensure consistency.
- Review the negative balance in the SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - ADS) to understand if additional blocklisting was required to cover the 922,341 shares issued.
- Confirm the impact of the 19,638 shares transferred from the GSK Trust to directors/participants on January 18, 2005, regarding potential dilution or insider trading reporting requirements.
- Note that this filing contains no operational or financial performance data; investors must refer to the company's Form 20-F or interim financial statements for revenue and profit analysis.